Short-Term Outcomes of COVID-19 Pandemic on Non-Small Cell Lung Cancer Screening and Management

Abstract

Background To assess the impact of coronavirus disease 2019 (COVID-19) pandemic on non-small cell lung cancer (NSCLC) screening, staging, and management in a single health care system.

Materials and Methods From November 2015 to December 2020, a total of 1,547 NSCLC cases was reported at our institution including 1,329 cases pre-COVID-19 and 218 cases during COVID-19. Pre-COVID-19 was defined as November 2015 to February 2020, while during COVID-19 was March 2020 to December 2020. Data were collected from tumor registry and medical record review. Patients with mesothelioma, lymphoma, small cell, or mixed small cell cancer were excluded from the study.

Results Both pre-COVID-19 and during COVID-19 cohorts had similar comorbidities including age (70 vs. 71 years), current smokers (35 vs. 32%), and chronic obstructive lung disease (32 vs. 28%). The number of low-dose computed tomography lung cancer screening scans decreased by 25% during COVID-19 compared with pre-COVID-19 era. There were more cases of stage 1A NSCLC pre-COVID-19 (31 vs. 25%) and more stage 4 cancer during COVID-19 (42 vs. 33%); p = 0.01. The proportion of patients treated with radiotherapy was similar between pre-COVID-19 and during COVID-19 (49 vs. 50%), but fewer patients underwent surgery during COVID-19 (17 vs. 27%; p = 0.004). The median time to radiotherapy (67 days) and surgery (29 days) was similar between the groups. The unadjusted overall 6-month mortality after lung cancer diagnoses was higher during COVID-19 compared with pre-COVID-19 (28 vs. 22%; p = 0.04).

Conclusion The COVID-19 pandemic resulted in delayed lung cancer screening scans, and more patients had diagnosis of advanced NSCLC; however, short-term mortality was unchanged.

Keywords

COVID-19 - non-small cell lung cancer - radiotherapy - surgical management

Note

This article was presented at Academic Surgical Congress 2023.

Authors' contribution

All authors contributed equally to the study conception and design, analysis and interpretation, data collection, writing the article, critical revision of the article, and obtaining funding.

Publikationsverlauf

Eingereicht: 17. Oktober 2023

Angenommen: 29. November 2023

Artikel online veröffentlicht:
20. Dezember 2023

• References

• 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
• 2 Goldstraw P, Chansky K, Crowley J. et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11 (01) 39-51
• 3 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
• 4 Samson P, Patel A, Garrett T. et al. Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2015; 99 (06) 1906-1912 , discussion 1913
• 5 Huang CS, Hsu PK, Chen CK, Yeh YC, Shih CC, Huang BS. Delayed surgery after histologic or radiologic-diagnosed clinical stage I lung adenocarcinoma. J Thorac Dis 2020; 12 (03) 615-625
• 6 Broderick SR, Grau-Sepulveda M, Kosinski AS. et al. The society of thoracic surgeons composite score rating for pulmonary resection for lung cancer. Ann Thorac Surg 2020; 109 (03) 848-855
• 7 Turaga KK, Girotra S. Are We Harming Cancer Patients by Delaying Their Cancer Surgery During the COVID-19 Pandemic?. Ann Surg 2023; Nov 1; 278 (05) e960-e965
• 8 Heiden BT, Eaton Jr DB, Engelhardt KE. et al. Analysis of delayed surgical treatment and oncologic outcomes in clinical stage I non–small cell lung cancer. JAMA Netw Open 2021; 4 (05) e2111613
• 9 Patt D, Gordan L, Diaz M. et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 2020; 4: 1059-1071
• 10 Kasymjanova G, Anwar A, Cohen V. et al. The impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian Academic Center: a retrospective chart review. Curr Oncol 2021; 28 (06) 4247-4255
• 11 Potter AL, Rosenstein AL, Kiang MV. et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ 2022; 376: e069008
• 12 de Koning H, van der Aalst C, Haaf KT. et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population-based trial. J Thorac Oncol 2018; 13: S185
• 13 Cantini L, Mentrasti G, Russo GL. et al. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open 2022; 7 (02) 100406
• 14 Mynard N, Saxena A, Mavracick A. et al. Lung cancer stage shift as a result of COVID-19 lockdowns in New York City, a brief report. Clin Lung Cancer 2022; 23 (03) e238-e242
• 15 Garassino MC. et al COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020; Jul; 21 (07) 914-922
• 16 Kabarriti R, Brodin NP, Maron MI. et al. Extent of prior lung irradiation and mortality in COVID-19 patients with a cancer history. Adv Radiat Oncol 2020; 5 (04) 707-710
• 17 Hong JH, Park S, Kim H. et al. Volume and mass doubling time of lung adenocarcinoma according to WHO histologic classification. Korean J Radiol 2021; 22 (03) 464-475